Type of information: Presentation of results at a congress
Announcement: presentation of results at the PEGS Third Annual Agonist Immunotherapy Targets conference in Boston
Company: Alligator Bioscience (Sweden)
Action mechanism: bispecific antibody. ATOR-1015 is a bispecific antibody for tumor-directed immunotherapy and is fully owned and developed by Alligator for the treatment of metastatic cancer. ATOR-1015 binds to two different immune receptors: the checkpoint receptor CTLA-4, and the co-stimulatory receptor OX40. ATOR-1015 is developed to reduce immune suppressive functions including regulatory T cells, as well as to induce direct T-cell activation. The immune activation is augmented in areas where both target molecules are expressed at high levels, notably in the tumor microenvironment, which is believed to reduce adverse immune reactions.
Therapeutic area: Cancer - Oncology